Key Findings
- AOD-9604 is being developed for weight‑loss/obesity.
- Metabolic started Phase IIa trials by February 2002.
- No efficacy, safety, or dosage details are reported.
Practical Outcomes
- For biohackers, the peptide is still in early clinical testing with no publicly available data on how it works or how to use it. It’s not ready for self‑experimentation or protocol design at this stage.
Summary
AOD-9604 is a peptide that Metabolic is testing as a possible obesity treatment, and by early 2002 it had entered Phase IIa clinical trials. No results, dosing info, or safety data are provided in the abstract.
Abstract
Metabolic is developing AOD-9604 for the potential treatment of obesity. By February 2002, phase IIa trials were underway.
Study Information
Provider
pubmed
Year
2004